Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus SOX chemotherapy with or without intraperitoneal nab-paclitaxel in HER2-negative gastric/GEJ adenocarcinoma with peritoneal metastasis
ChiCTR2600117422Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sintilimab, oxaliplatin, tegafur and paclitaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and peritoneal carcinomatosis (PC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Overall Survival. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sintilimaboxaliplatintegafurpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR2600117422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117422.